15th January 2021
16:26

Vectura Group plc - Statement re Hikma Pharmaceuticals PLC update

12th January 2021
11:35
12th January 2021
07:02

Vectura Group plc - Trading Update

4th January 2021
13:00

Vectura Group plc - Total Voting Rights

30th December 2020
07:01

Vectura Group plc - Board Appointments

29th December 2020
09:45

Vectura Group plc - Update on GSK litigation

21st December 2020
11:18

Vectura Group plc - Holding(s) in Company

17th December 2020
17:31

Vectura Group plc - $11m milestone on US FDA Generic Advair approval

1st December 2020
15:03

Vectura Group plc - Total Voting Rights

30th November 2020
07:04

Vectura Group plc - Vectura agreement with Kinaset Therapeutics Inc.

19th November 2020
18:26

Vectura Group plc - Vectura provides update on GSK litigation

5th November 2020
14:49

Vectura Group plc - Director/PDMR Shareholding

16th October 2020
14:11

Vectura Group plc - Holding(s) in Company

15th October 2020
15:47

Vectura Group plc - Holding(s) in Company

15th October 2020
15:46

Vectura Group plc - Holding(s) in Company

1st October 2020
16:03

Vectura Group plc - Block listing six month return

1st October 2020
15:53

Vectura Group plc - Total Voting Rights

29th September 2020
06:00

Vectura Group plc - Transaction in Own Shares

28th September 2020
09:00

Vectura Group plc - Directorate Change

28th September 2020
06:01

Vectura Group plc - Transaction in Own Shares

Vectura Group Plc
VEC.L
Vectura Group Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    665.39M

Company Profile

Vectura develops inhaled therapies principally for the treatment of respiratory diseases.

Classification

Market Indices-
Watchlist